Doctor Hardean Achneck
Haemonetics Corporation, Braintree (United States of America)
Novel thromboelastography point-of-care test detects all commercially available DOACs at therapeutic concentrations and classifies them as direct thrombin or factor Xa inhibitors with high consistency
Event: ESC Congress 2018
Topic: Anticoagulants
Session: Bleeding risk and oral anticoagulation
ESC 365 is supported by
